In 2016, Tran et al. reported on a patient with metastatic CRC harboring a KRAS G12D mutation, and responding to TCR therapy recognizing peptide fragments of KRAS G12D presented by HLA molecules [153]. This evidence concerns the gene KRAS and colorectal carcinoma.